1. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (10th December 2020) Authors: Harris, Dean; Brungs, Daniel; Ladwah, Rahul; Mant, Andrew; McGrath, Margaret; Tazbirkova, Andrea; Akopov, Andrey; Fadeeva, Natalia; Kasparov, Boris; Kovalenko, Nadezhda; Kozlov, Vadim; Moiseenko, Fedor; Oschepkov, Vasiliy; Koralewski, Piotr; Kowalski, Dariusz; Lugowska, Iwona; Charoentumn, Chaiyu... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 399 Cosibelimab, an anti-PD-L1 antibody: preliminary safety and efficacy results from a global, multicohort phase 1 clinical trial. (9th November 2020) Authors: Harris, Dean; Brungs, Daniel; Ladwah, Rahul; Mant, Andrew; McGrath, Margaret; Tazbirkova, Andrea; Akopov, Andrey; Fadeeva, Natalia; Kasparov, Boris; Kovalenko, Nadezhda; Kozlov, Vadim; Moiseenko, Fedor; Oschepkov, Vasiliy; Koralewski, Piotr; Kowalski, Dariusz; Lugowska, Iwona; Charoentumn, Chaiyu... Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A424 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Issue 9992 (1st August 2015) Authors: Long, Georgina V; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandalà, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B A... Journal: Lancet Issue: Volume 386:Issue 9992(2015) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Issue 9992 (1st August 2015) Authors: Long, Georgina V; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandalà, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B A... Journal: Lancet Issue: Volume 386:Issue 9992(2015) Page Start: 444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗